home / stock / avcn:cc / avcn:cc quote
Last: | $0.37 |
---|---|
Change Percent: | 8.82% |
Open: | $0.34 |
Close: | $0.34 |
High: | $0.37 |
Low: | $0.34 |
Volume: | 38,750 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.37 | $0.34 | $0.34 | $0.37 | $0.34 | 38,750 | 08-02-2022 |
$0.295 | $0.3 | $0.295 | $0.3 | $0.29 | 76,390 | 05-06-2022 |
$0.31 | $0.35 | $0.31 | $0.35 | $0.305 | 107,470 | 05-05-2022 |
$0.365 | $0.38 | $0.365 | $0.38 | $0.32 | 47,601 | 05-04-2022 |
$0.385 | $0.41 | $0.385 | $0.41 | $0.37 | 59,172 | 05-03-2022 |
$0.395 | $0.39 | $0.395 | $0.415 | $0.39 | 71,861 | 05-02-2022 |
$0.405 | $0.4 | $0.405 | $0.43 | $0.38 | 405,312 | 04-29-2022 |
$0.375 | $0.31 | $0.375 | $0.38 | $0.31 | 450,876 | 04-28-2022 |
$0.29 | $0.27 | $0.29 | $0.29 | $0.27 | 125,390 | 04-27-2022 |
$0.27 | $0.28 | $0.27 | $0.28 | $0.265 | 21,979 | 04-26-2022 |
$0.27 | $0.25 | $0.27 | $0.27 | $0.25 | 70,531 | 04-25-2022 |
$0.25 | $0.26 | $0.25 | $0.265 | $0.25 | 78,422 | 04-22-2022 |
$0.27 | $0.29 | $0.27 | $0.29 | $0.26 | 85,070 | 04-21-2022 |
$0.27 | $0.29 | $0.27 | $0.295 | $0.27 | 75,070 | 04-20-2022 |
$0.295 | $0.295 | $0.295 | $0.295 | $0.295 | 7,215 | 04-19-2022 |
$0.29 | $0.295 | $0.29 | $0.295 | $0.28 | 36,249 | 04-18-2022 |
$0.29 | $0.285 | $0.29 | $0.3 | $0.28 | 127,603 | 04-15-2022 |
$0.29 | $0.285 | $0.29 | $0.3 | $0.28 | 127,572 | 04-14-2022 |
$0.3 | $0.31 | $0.3 | $0.315 | $0.3 | 188,128 | 04-13-2022 |
$0.295 | $0.315 | $0.295 | $0.315 | $0.275 | 65,446 | 04-12-2022 |
News, Short Squeeze, Breakout and More Instantly...
Avicanna Inc. Company Name:
AVCN:CC Stock Symbol:
TSXC Market:
Best Quarterly Results in Company’s History from a Financial Perspective. EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies. Marketing Authorization of Trunerox™ in Colombia by INVIMA for Patients with LGS and DS in Colombia. ...
The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch. 55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability. TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ȁ...
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based pro...